INCYNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
INCYTE CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$113.25+0.18 (+0.16%)
Close on Oct 19, 2026
- Market cap
- $23.58B
- P/E (TTM)
- 14.4
- Dividend yield
- –
INCYTE CORP revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | $4.35B | $3.62B | $3.17B | $2.75B | $2.32B | $2.07B | $1.77B | $1.47B | $1.20B | $882.40M | 84.7% | +20.3% |
| JAKAFI | $3.09B | $2.79B | $2.59B | $2.41B | $2.13B | $1.94B | $1.68B | $1.39B | $1.13B | $852.82M | 60.2% | +10.8% |
| OPZELURA | $678.46M | $508.29M | $337.86M | $128.74M | $4.67M | $0 | – | – | – | – | 13.2% | +33.5% |
| Product royalty revenues | $636.91M | $579.33M | $523.48M | $482.74M | $569.26M | $392.97M | $306.34M | $234.78M | $160.79M | $110.71M | 12.4% | +9.9% |
| JAKAVI | $457.73M | $418.84M | $367.58M | $331.58M | $337.99M | $277.90M | – | – | – | – | 8.9% | +9.3% |
| NIKTIMVO | $151.64M | $0 | $0 | – | – | – | – | – | – | – | 2.9% | – |
| Milestone and contract revenues | $150.00M | $43.00M | $7.00M | $165.00M | $95.00M | – | – | – | – | – | 2.9% | +248.8% |
| OLUMIANT Royalty Revenues | $144.60M | $135.57M | $136.14M | $134.55M | $220.88M | $110.92M | $80.42M | $40.09M | $9.11M | – | 2.8% | +6.7% |
| MINJUVI/MONJUVI | $144.58M | $119.24M | $37.06M | $19.65M | – | – | – | – | – | – | 2.8% | +21.3% |
| ICLUSIG | $134.07M | $114.32M | $111.62M | $105.84M | $109.40M | $105.00M | $89.95M | $79.94M | $66.92M | $29.59M | 2.6% | +17.3% |
| PEMAZYRE | $86.73M | $81.75M | $83.64M | $83.45M | $68.53M | $25.88M | $89.95M | – | – | – | 1.7% | +6.1% |
| ZYNYZ | $66.35M | $3.19M | $1.25M | $0 | $0 | – | – | – | – | – | 1.3% | +1983.2% |
| TABRECTA | $26.70M | $22.75M | $17.79M | $15.41M | $10.39M | $4.14M | – | – | – | – | 0.5% | +17.4% |
| Other | $7.88M | $2.17M | $1.97M | – | – | – | – | – | – | – | 0.2% | +262.9% |
| Other revenues | – | – | – | – | – | – | – | $203.00K | $113.00K | $92.00K | – | – |
| Milestone and contract revenues | – | – | – | $165.00M | $95.00M | $205.00M | $77.50M | $180.00M | $175.00M | $112.51M | – | – |
| JAKAVI Royalty Revenues | – | – | – | – | $337.99M | $277.90M | $225.91M | $194.69M | $151.68M | $110.71M | – | – |
| TABRECTA Royalty Revenues | – | – | – | – | $10.39M | $4.14M | – | – | – | – | – | – |
| MINJUVI | – | – | $37.06M | $19.65M | $4.91M | $0 | – | – | – | – | – | – |
| PEMAZYRE Royalty Revenues | – | $2.17M | $1.97M | $1.21M | $0 | $0 | – | – | – | – | – | – |
| OPZELURA | – | – | – | – | $4.91M | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $4.80B | $3.97B | $3.51B | $3.20B | $2.90B | $2.60B | $2.10B | $1.80B | $1.50B | $1.10B | 93.4% | +20.8% |
| Europe | $323.73M | $260.44M | $175.87M | $147.00M | $124.10M | $105.00M | $90.00M | $79.90M | $66.90M | $29.60M | 6.3% | +24.3% |
| Other countries | $17.57M | $6.21M | $4.91M | – | – | – | – | – | – | – | 0.3% | +182.7% |
| Europe and Japan | – | – | $179.30M | – | – | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Incyte's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.